NantWorks, LLC
http://www.nantworks.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NantWorks, LLC
Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing
Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.
Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Keeping Track, Oncology Edition: Biologic Breakthroughs And BLAs
The latest oncology development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Diversified
- In Vitro Diagnostics
-
Medical Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- Altor BioScience Corporation
- Altor BioScience, LLC
- IgDraSol, Inc.
- ImmunityBio, Inc.
- NantHealth
- NantMobile
- NantMedia
- NantOmics
- NantBioScience
- NantCell, Inc.
- NantPharma
- NantCapital
- NantCloud
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice